Abstract
Key Takeaways: • The prevalence of CMV infection among patients with IBD ranges from 2 to 29%, with a higher prevalence in those with UC compared to CD. • Immunohistochemistry and tissue PCR, or both, are the recommended tests for diagnosing active CMV colitis. • CMV may be an active pathogenic participant in cases with a high density of CMV and severe disease activity. Thus, we recommend testing for CMV colitis in patients with a severe inflammatory burden who are not responding to conventional IBD therapy. • Patients with low CMV viral burden can likely be treated with immunosuppression alone, while patients with high viral density or medically refractory disease should be treated with antiviral therapy.

This publication has 25 references indexed in Scilit: